TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12855344

Group type: EXPERIMENTAL
Intervention: Momentary monitoring of pain with an electronic diary
Number of subjects: 91
Study: 10673886

Group type: EXPERIMENTAL
Intervention: Remifentanil 1 microgram kg‐1
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 8607397

Group type: EXPERIMENTAL
Intervention: Flecainide (median dose, 200 mg/day)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Verapamil (median dose, 240 mg/day)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 121

Group type: COMPARATOR
Intervention: Verapamil
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 121
Study: 1850344

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (0.6 mg/kg/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 6171491

Group type: EXPERIMENTAL
Intervention: Dextran‐40
Number of subjects: 57

Group type: COMPARATOR
Intervention: Hartman's solution
Number of subjects: 57
Study: 31797446

Group type: EXPERIMENTAL
Intervention: Empowerment program (12-week program including intensive counseling, education, and telephone calls)
Number of subjects: 115
Study: 31008987

Group type: EXPERIMENTAL
Intervention: Novel circumcision method (subcutaneous tissue-sparing dorsal slit with new marking)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Conventional dissection
Number of subjects: 93
Study: 28275838

Group type: EXPERIMENTAL
Intervention: Catch a Break (CaB) FLS
Number of subjects: 7323
Study: 26116491

Group type: EXPERIMENTAL
Intervention: Supervised Toothbrushing (STB)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Composite Resin (CR)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Atraumatic Restorative Treatment - High-Viscosity Glass-Ionomer Cement (ART-GIC)
Number of subjects: 242

Group type: COMPARATOR
Intervention: No Intervention
Number of subjects: 242
Study: 23363655

Group type: EXPERIMENTAL
Intervention: HIV prevention program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-esteem
Number of subjects: 0
Study: 21052775

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with ACNU (40 mg/m(2)/day) and CDDP (40 mg/m(2)/day) infused continuously for 72 h followed by radiotherapy and adjuvant temozolomide (150‐200 mg/m(2) for 5 days every 28 days)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Radiotherapy followed by adjuvant temozolomide (150‐200 mg/m(2) for 5 days every 28 days)
Number of subjects: 82
Study: 19671350

Group type: EXPERIMENTAL
Intervention: upstream tirofiban (4-6 hours prior to PCI)
Number of subjects: 160

Group type: COMPARATOR
Intervention: downstream tirofiban (immediately prior to PCI)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: upstream tirofiban
Number of subjects: 160

Group type: COMPARATOR
Intervention: downstream tirofiban
Number of subjects: 160
Study: 17237646

Group type: EXPERIMENTAL
Intervention: Minimal extracorporeal circuit (MECC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional cardiopulmonary bypass (CPB)
Number of subjects: 60
Study: 15093577

Group type: EXPERIMENTAL
Intervention: Doxorubicin and paclitaxel
Number of subjects: 275

Group type: COMPARATOR
Intervention: Doxorubicin and cyclophosphamide
Number of subjects: 275
Study: 14556826

Group type: EXPERIMENTAL
Intervention: Short coincubation of gametes for 2 hours (group 1)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Prolonged incubation of gametes for 20 hours (group 2)
Number of subjects: 259
Study: 10446118

Group type: EXPERIMENTAL
Intervention: Lipid emulsion containing long chain triglycerides
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lipid emulsion containing a mixture of long and medium chain triglycerides
Number of subjects: 30
Study: 8848889

Group type: EXPERIMENTAL
Intervention: Ephedrine (5 mg intravenous bolus injections)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Phenylephrine (40 micrograms intravenous bolus injections)
Number of subjects: 40
Study: 2081789

Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin (500 mg/kg)
Number of subjects: 577

Group type: COMPARATOR
Intervention: Placebo (5% albumin-normal saline, 10 ml/kg)
Number of subjects: 577
Study: 6986007

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg oxatomide b.i.d.
Number of subjects: 91

Group type: COMPARATOR
Intervention: 0.4 mg/kg diphenhydramine b.i.d.
Number of subjects: 91
Study: 31752042

Group type: EXPERIMENTAL
Intervention: Routine GPI administration before primary PCI
Number of subjects: 1630

Group type: EXPERIMENTAL
Intervention: Bailout GPI administration
Number of subjects: 1630

Group type: COMPARATOR
Intervention: No GPI
Number of subjects: 1630

Group type: EXPERIMENTAL
Intervention: Routine GPI administration
Number of subjects: 1630
Study: 30730541

Group type: EXPERIMENTAL
Intervention: rAAV2/2-ND4 (9×109, 3×1010, 9×1010, and 1.8×1011 viral genomes per eye) as a single unilateral intravitreal injection
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: rAAV2/2-ND4
Number of subjects: 15
Study: 28760390

Group type: EXPERIMENTAL
Intervention: Tobacco Heating System (THS) 2.2
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Cigarettes (CC)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Nicotine Gum (Gum)
Number of subjects: 62
Study: 25047652

Group type: EXPERIMENTAL
Intervention: Electrodiagnostic testing with physical therapy (specific interventions not detailed)
Number of subjects: 38
Study: 24043742

Group type: EXPERIMENTAL
Intervention: Simple intensity-modulated radiotherapy (IMRT)
Number of subjects: 1145

Group type: COMPARATOR
Intervention: Standard radiotherapy (RT)
Number of subjects: 1145
Study: 21544070

Group type: EXPERIMENTAL
Intervention: Cabergoline (DA agonist)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Methylphenidate (indirect NE agonist)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Tacrine (ACh agonist)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Haloperidol (DA antagonist)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Prazosine (NE antagonist)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Biperiden (ACh antagonist)
Number of subjects: 8
Study: 19039224

Group type: EXPERIMENTAL
Intervention: levodopa/DDCI and entacapone
Number of subjects: 0

Group type: COMPARATOR
Intervention: dose fractionation
Number of subjects: 0
Study: 17726362

Group type: EXPERIMENTAL
Intervention: Combined endurance and resistance training (3 hours a week for one year)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no change in everyday activities)
Number of subjects: 40
Study: 15205602

Group type: EXPERIMENTAL
Intervention: Electrochemotherapy with cisplatin
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intratumoral (i.t.) administration of cisplatin
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 6
Study: 11349741

Group type: EXPERIMENTAL
Intervention: Subcutaneous fludarabine 30 mg/m2/day
Number of subjects: 5

Group type: COMPARATOR
Intervention: Intravenous fludarabine 30 mg/m2/day
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Subcutaneous fludarabine
Number of subjects: 5

Group type: COMPARATOR
Intervention: Intravenous fludarabine
Number of subjects: 5
Study: 9847430

Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 16
Study: 30793735

Group type: EXPERIMENTAL
Intervention: Home monitoring-only (HMo) based on remote monitoring (RM) + remote interrogations (RIs) every 6 months
Number of subjects: 445

Group type: COMPARATOR
Intervention: HM + IO (Home Monitoring + In-Office evaluations) every 6 months
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Home monitoring-only (HMo)
Number of subjects: 445

Group type: COMPARATOR
Intervention: HM + IO
Number of subjects: 445
Study: 28831241

Group type: EXPERIMENTAL
Intervention: Canrenone 50 mg
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Canrenone 100 mg
Number of subjects: 158

Group type: COMPARATOR
Intervention: Control (ACE inhibitors or AT1R antagonists plus HCT without canrenone)
Number of subjects: 158
Study: 25367200

Group type: EXPERIMENTAL
Intervention: Self-adhesive mesh (Parietene Progrip®)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Conventional Lichtenstein hernioplasty (polypropylene mesh)
Number of subjects: 89
Study: 23826214

Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS of the left dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS of the medial prefrontal cortex (MPFC)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 18
Study: 19329547

Group type: COMPARATOR
Intervention: 50 mg LDX
Number of subjects: 36

Group type: COMPARATOR
Intervention: 100 mg LDX
Number of subjects: 36

Group type: COMPARATOR
Intervention: 150 mg LDX
Number of subjects: 36

Group type: COMPARATOR
Intervention: 40 mg d-amphetamine
Number of subjects: 36

Group type: COMPARATOR
Intervention: 200 mg diethylpropion
Number of subjects: 36
Study: 17505429

Group type: EXPERIMENTAL
Intervention: Endovascular treatment (ET) using Hemobahn/Viabahn endograft
Number of subjects: 42

Group type: COMPARATOR
Intervention: Open repair (OR)
Number of subjects: 42
Study: 15730073

Group type: EXPERIMENTAL
Intervention: Video-based intervention
Number of subjects: 116

Group type: COMPARATOR
Intervention: Standard advocate services alone
Number of subjects: 116
Study: 12470020

Group type: EXPERIMENTAL
Intervention: IRM
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cavit
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Dyract
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (positive)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (negative)
Number of subjects: 15
Study: 9447858

Group type: EXPERIMENTAL
Intervention: Low-dose ondansetron (50 microg/kg) plus dexamethasone (150 microg/kg)
Number of subjects: 197

Group type: COMPARATOR
Intervention: High-dose ondansetron (150 microg/kg)
Number of subjects: 197
Study: 8581393

Group type: EXPERIMENTAL
Intervention: 35 Gy in 10 fractions (43 patients)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 45 Gy in 15 fractions (41 patients)
Number of subjects: 84
Study: 2243152

Group type: EXPERIMENTAL
Intervention: Diphenhydramine hydrochloride 12.5 mg
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Diphenhydramine hydrochloride 25 mg
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Diphenhydramine hydrochloride 50 mg
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Diphenhydramine hydrochloride (all doses)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Diphenhydramine hydrochloride
Number of subjects: 144
Study: 369470

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: COMPARATOR
Intervention: No drug
Number of subjects: 20
Study: 30535716

Group type: EXPERIMENTAL
Intervention: Fan Technique (FT)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Free Hand Technique (FH)
Number of subjects: 6
Study: 28393632

Group type: EXPERIMENTAL
Intervention: Informed about the gift card prize-draw incentive
Number of subjects: 433

Group type: COMPARATOR
Intervention: Not informed about the prize-draw
Number of subjects: 433
Study: 25111429

Group type: EXPERIMENTAL
Intervention: Brief motivational interventions (BMIs)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Higher therapist ratings of MI Spirit
Number of subjects: 249
Study: 23453899

Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Low dose, metronomic cyclophosphamide + methotrexate (CM)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Both PLD and CM
Number of subjects: 77
Study: 21183370

Group type: EXPERIMENTAL
Intervention: Levetiracetam 3000 mg/day
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 19859541

Group type: EXPERIMENTAL
Intervention: DENV3 infection with low anti-DENV3 neutralizing activity (PRNT(50) <=50) and measurable DENV3 ADE activity
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Higher weight-for-age in the first 3 months of life and at illness presentation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: DENV3 PRNT(50) >50
Number of subjects: 60
Study: 17498015

Group type: EXPERIMENTAL
Intervention: 1 MAC sevoflurane (up to 5%)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 1 MAC halothane (up to 1.5%)
Number of subjects: 20
Study: 15356567

Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg once daily (monotherapy)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg once daily plus Montelukast 10 mg once daily (combined therapy)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Montelukast 10 mg once daily (monotherapy)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 11668104

Group type: EXPERIMENTAL
Intervention: Topical glyceryl trinitrate (GTN) paste
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 9678778

Group type: EXPERIMENTAL
Intervention: Probucol (P)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Low-cholesterol diet (D)
Number of subjects: 24
Study: 7985631

Group type: EXPERIMENTAL
Intervention: Preterm formula (n = 12)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Human milk (n = 6)
Number of subjects: 29
Study: 2919572

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Active cognitive strategy
Number of subjects: 20
Study: 29993839

Group type: EXPERIMENTAL
Intervention: IGRSVD algorithm using randomized singular value decomposition (RSVD) and ODE-based optimization.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Existing SVD algorithm and PCA_CMI algorithm (control group).
Number of subjects: 0
Study: 28433798

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) 250 IU/kg daily during the first 6 days of life
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 23985135

Group type: EXPERIMENTAL
Intervention: Cognitive training (12 weeks)
Number of subjects: 37
Study: 22814893

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (830 nm), 100 mW, applied for 20 s per point (5 J/cm²)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo treatment (placebo light)
Number of subjects: 20
Study: 21971473

Group type: EXPERIMENTAL
Intervention: Cognitive intervention groups (IGs) receiving weekly sessions of group‐based multicomponent cognitive intervention
Number of subjects: 39

Group type: COMPARATOR
Intervention: Active control groups (CGs) receiving pencil‐paper exercises for self‐study
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Cognitive intervention groups (IGs)
Number of subjects: 39
Study: 19122109

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17406886

Group type: EXPERIMENTAL
Intervention: Endurance training (16-week walking training)
Number of subjects: 20
Study: 14963471

Group type: COMPARATOR
Intervention: PT-141 (doses greater than 7 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PT-141
Number of subjects: 0
Study: 12074226

Group type: EXPERIMENTAL
Intervention: Whitening strips with 5.3% hydrogen peroxide bleaching gel (Crest Whitestrips)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo strips without hydrogen peroxide
Number of subjects: 57
Study: 9802373

Group type: EXPERIMENTAL
Intervention: 0.03% tacrolimus ointment
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 0.1% tacrolimus ointment
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 0.3% tacrolimus ointment
Number of subjects: 180

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Tacrolimus-treated patients
Number of subjects: 180

Group type: COMPARATOR
Intervention: Vehicle-treated patients
Number of subjects: 180
Study: 7641661

Group type: EXPERIMENTAL
Intervention: Social support during a stressful speech task
Number of subjects: 104

Group type: COMPARATOR
Intervention: No social support during a stressful speech task
Number of subjects: 104
Study: 2746750

Group type: EXPERIMENTAL
Intervention: Cefoperazone
Number of subjects: 110

Group type: COMPARATOR
Intervention: No antibiotic prophylaxis
Number of subjects: 110
Study: 866705

Group type: EXPERIMENTAL
Intervention: Prostaglandins in a viscous medium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 0
Study: 31782828

Group type: EXPERIMENTAL
Intervention: Medical screen during dressing changes (N = 26)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Regular dressing changes (Control group, N = 26)
Number of subjects: 52
Study: 31637444

Group type: EXPERIMENTAL
Intervention: Systemic therapy plus intrathecal liposomal cytarabine (median 5 injections, range 1-20)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Systemic therapy alone (control group)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Systemic therapy plus intrathecal liposomal cytarabine
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Quality of life until progression
Number of subjects: 73
Study: 29800954

Group type: EXPERIMENTAL
Intervention: Adjuvant Radiotherapy (RT)
Number of subjects: 3213
Study: 26712187

Group type: EXPERIMENTAL
Intervention: High dairy group
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Low dairy group
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65
Study: 24024499

Group type: EXPERIMENTAL
Intervention: GFR(cys)
Number of subjects: 4614

Group type: EXPERIMENTAL
Intervention: GFR(cr)
Number of subjects: 4614

Group type: EXPERIMENTAL
Intervention: GFR(cr-cys)
Number of subjects: 4614
Study: 22663903

Group type: EXPERIMENTAL
Intervention: Mom‐Net (8‐session, Internet‐facilitated intervention)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Delayed intervention/facilitated treatment‐as‐usual (DI/TAU)
Number of subjects: 70
Study: 20646514

Group type: EXPERIMENTAL
Intervention: Optimized group (midazolam 0.06 mg/kg, fentanyl 1 mg/kg at 1 min later, vecuronium 0.1 mg/kg at 1 min 55 s, propofol 1.5‐2 mg/kg at 2 min, second dose of 3 mg/kg fentanyl at 2 min 20 s)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (fentanyl 4 mg/kg injected at time 1 min)
Number of subjects: 120
Study: 18948243

Group type: EXPERIMENTAL
Intervention: Partial lower sternotomy (group 1, n = 26)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Right anterolateral thoracotomy via a submammary incision (group 2, n = 34)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Conventional median sternotomy (group 3, n = 22)
Number of subjects: 82
Study: 15964387

Group type: EXPERIMENTAL
Intervention: Mycophenolic acid (MPA) monitoring using limited sampling strategy (LSS)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Mycophenolic acid (MPA) monitoring using four samples
Number of subjects: 9
Study: 11846843

Group type: EXPERIMENTAL
Intervention: Emdogain
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control
Number of subjects: 28
Study: 10527996

Group type: COMPARATOR
Intervention: Trimegestone-based sequential hormone replacement therapy (HRT) with doses of 0.05, 0.1, 0.25, and 0.5 mg per day of trimegestone from day 15 to day 28, combined with continuous micronized oestradiol 2 mg daily for six treatment cycles
Number of subjects: 0

Group type: COMPARATOR
Intervention: Natural cycle (control group)
Number of subjects: 0
Study: 7579312

Group type: EXPERIMENTAL
Intervention: Regimen 1: rifampicin, isoniazid and pyrazinamide daily for an initial 3 months followed by rifampicin and isoniazid twice‐weekly for 6 months.
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Regimen 2: rifampicin, isoniazid and pyrazinamide thrice‐weekly for an initial 3 months followed by rifampicin and isoniazid twice‐weekly for 6 months.
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Regimen 1
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Regimen 2
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 108
Study: 1789404

Group type: EXPERIMENTAL
Intervention: Washed gloves
Number of subjects: 3

Group type: COMPARATOR
Intervention: Non-washed gloves
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Sterilized gloves (120 degrees C for 1 h in saturated steam)
Number of subjects: 3
Study: 7138753

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Oxprenolol 80 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Propranolol (twice a day for 2 weeks)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Oxprenolol (twice a day for 2 weeks)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Propranolol (6 weeks treatment)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Oxprenolol (6 weeks treatment)
Number of subjects: 8
Study: 31907032

Group type: EXPERIMENTAL
Intervention: Exposure-based therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Behavioral activation therapy
Number of subjects: 0
Study: 31268130

Group type: EXPERIMENTAL
Intervention: MSI/dMMR tumors
Number of subjects: 2630

Group type: EXPERIMENTAL
Intervention: Standard oxaliplatin-based adjuvant chemotherapy regimens
Number of subjects: 2630

Group type: EXPERIMENTAL
Intervention: MSI/dMMR tumors lacking BRAFV600E
Number of subjects: 2630

Group type: EXPERIMENTAL
Intervention: MSI/dMMR tumors harboring BRAFV600E
Number of subjects: 2630

Group type: COMPARATOR
Intervention: Tumors with BRAFV600E
Number of subjects: 2630

Group type: EXPERIMENTAL
Intervention: MSI/dMMR tumors with BRAFV600E
Number of subjects: 2630
Study: 27037801

Group type: EXPERIMENTAL
Intervention: EndoREZ
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ActiV GP
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: AH Plus/gutta‐percha
Number of subjects: 30
Study: 25631113

Group type: EXPERIMENTAL
Intervention: PINQ-PHONE (telephone questionnaire)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Negative responses to PINQ-PHONE
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Overall sensitivity of PINQ-PHONE
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Overall specificity of PINQ-PHONE
Number of subjects: 300
Study: 24420556

Group type: EXPERIMENTAL
Intervention: Cisplatin and etoposide plus concurrent and sequential sorafenib 200 mg orally bid for four cycles, then 400 mg orally bid as maintenance for up to 12 months after no disease progression.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Cisplatin and etoposide plus concurrent and sequential sorafenib.
Number of subjects: 18